Compare Ascendis Pharma A/S (ASND) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while GraniteShares 2x Long COIN Daily ETF trades at $4.85. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| ASND | CONL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $64.57 |
52-Week Low | $163.32 | $4.09 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.95 with a slight 0.61% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (June 6, 2026), reflecting the amplified risks of daily-reset leverage on Coinbase stock performance.
The outlook remains highly speculative with potential for explosive gains if Bitcoin rallies toward $100,000, but investors face substantial volatility decay risks. Recent cryptocurrency momentum provides short-term catalysts, though the leveraged structure makes CONL suitable only for sophisticated traders comfortable with rapid capital erosion during market whipsaws.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
